SCHEMBL13216618

SCHEMBL13216618

CC(C)C1(C)NC(=O)N(C)C1=O

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13199769 0.76 CNR1 (0.33) POLB
SCHEMBL4622057 0.71 TSHR (0.33) TSHRCYP2C19
SCHEMBL3126654 0.70 POLB (0.52) TSHRCYP2C19LMNAPOLB
SCHEMBL9257470 0.70
SCHEMBL24133231 0.69 TSHR (0.37) TSHRCYP2C19LMNAPOLB
SCHEMBL16553553 0.68 TSHR (0.38) TSHRCYP2C19LMNAPOLB
SCHEMBL6239127 0.67 TSHR (0.36) TSHRCYP2C19LMNAPOLB
SCHEMBL1362082 0.67 TSHR (0.36) TSHRCYP2C19LMNAPOLB
SCHEMBL11769603 0.65 AR (0.35) TSHRPOLB
SCHEMBL15026088 0.64 CYP2C19 (0.46) TSHRCYP2C19LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772433-B2 SARMS and method of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2010-08-10 US disclosed
US-20080057068-A1 SARMS and method of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080057068-A1 SARMS and method of use thereof SARM1, CKMT1A; CKMT1B, TNNI3 TSHR 2773/4885CYP2C19 4452/4885LMNA 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.